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"What message are we sending to young people who are trans or gender 
nonconforming when we don’t even count them?  We suggest their identities don't 
even matter."  
Laverne Cox, 2015 Social Good Summit 
 
 
Trans and non-binary people are key populations whose HIV prevention and 
treatment needs have been neglected. A 2013 meta-analysis of data from 39 studies 
conducted in 15 countries, reported a global HIV prevalence among trans women of 
nearly 20%, with trans women estimated to be 49 times more likely than other adults 
to be living with HIV1.  Moreover, mortality from HIV/AIDS among trans women in a 
large cohort study was just over 30 times that of age-matched population controls2.  
 
Data on HIV among trans and non-binary people in the United Kingdom (UK), 
data are scant. This is important as HIV prevalence among trans people may differ 
from global estimates given lower rates of undiagnosed HIV infection in the UK, high 
levels of viral suppression, and access to free healthcare. Prior to 2014, HIV 
surveillance systems in England used binary gender identity categories, rendering 
trans and non-binary populations living with HIV invisible.  In 2017, Public Health 
England (PHE) presented preliminary data from the HIV and AIDS Reporting System 
(HARS), reporting that 199 trans adults accessed HIV care in 2016, representing 
0.3% of all people accessing HIV care in England (personal communication, P 
Kirwan, Public Health England, 03 May 2018).   Of note, these data reveal that trans 
adults with HIV were twice as likely as other adults to be diagnosed late with a CD4 
count of <350mm3.    It is not possible to determine accurately the HIV prevalence 
among trans women and men in the UK because there are currently no census data 
on the overall number of persons who identify as trans or non-binary in the UK.  
What message indeed are we sending to trans people when we do not even count 
them?  
 
Trans and non-binary people may experience a constellation of social 
stressors and structural inequalities placing them at increased risk of HIV infection.  
Stonewall’s recently published Trans Report makes for sobering reading3.  Two-in-
five trans people have experienced a hate crime because of their gender identity in 
the last 12 months.  More than a quarter of trans people in a relationship have faced 
domestic abuse from a partner. One-in-four have experienced homelessness.  This 
complex interplay of social vulnerability and widespread transphobia can impact 
mental health, manifesting in alcohol and substance misuse4 and an increased risk 
of depression, anxiety and suicidal ideation5, all of which are in turn associated with 
an elevated risk of HIV acquisition. Workplace discrimination, poverty and 
homelessness may place trans people at further risk of HIV.  There is a higher 
prevalence of history of sex work in trans women than in other groups6.  International 
data reveal a higher prevalence of HIV among trans women sex workers compared 
to cis-gender sex workers, and suggest that condomless sex for economic survival 
or as a result of sexual violence are important contributing factors7.  A small study 
from the UK showed a similar high HIV prevalence (37.5%) among trans sex 
workers, almost all of whom were trans women8.   
 
  With the widespread availability of condoms, the increasing adoption of 
treatment as prevention (TasP) and the advent of pre-exposure prophylaxis (PrEP), 
we have entered a new era in which ending HIV transmission seems possible. Trans 
and non-binary people may experience particular challenges in accessing and 
adopting HIV prevention interventions. For instance, among trans women, poor 
mental health and gender-based violence can constrain their capacity to negotiate 
condom use9. Furthermore, we have limited data on PrEP awareness, acceptability 
and uptake in trans and non-binary people.  Some of the landmark PrEP trials have 
included trans women as participants, although many have either misclassified trans 
women’s gender identities or have not disaggregated data from trans women from 
those from men who have sex with men.  A post-hoc sub-group analysis of data on 
339 trans women in the iPrEx trial revealed a high number of HIV seroconversions in 
the intervention group, all linked to poor adherence10.  In this analysis, trans women 
who reported use of feminising hormones were less likely to have detectable drug 
levels10.  One of the only studies to date in the UK, a survey of 44 trans people 
testing for HIV at a sex-on-premises venue in London, found that over two-thirds 
reported no knowledge of PrEP or post-exposure prophylaxis (PEP), with many 
expressing concerns about cost, reliability and potential drug interactions with 
hormone therapy11.  
 
We know that trans people experience significant barriers to accessing 
healthcare, including HIV care.  The 2016 People Living with HIV Stigma Survey 
demonstrated widespread concerns among a small sample of 31 trans people living 
with HIV about being treated differently by healthcare providers across a range of 
settings, with substantial numbers avoiding healthcare as a result12.   Other factors 
that could potentially impact retention in HIV care and adherence to ART among 
trans women include concerns about potential drug interactions between ART and 
hormone therapy, and the psychosocial factors outlined earlier13.  A recent case-
notes review of 32 trans women attending a clinic in London for HIV care found that 
nearly a third had taken a break from their antiretroviral therapy, and that one fifth 
had a detectable HIV viral load compared to 4% among cis-gender patients 
attending the general HIV service14.   In contrast, preliminary data from HARS have 
shown similar levels of virological suppression in trans and cis-gender people 
accessing HIV care in the UK  (personal communication, P Kirwan, Public Health 
England, 03 May 2018).  Further data are required to better characterise and 
understand the HIV care continuum among trans women in the UK  
 
    Trans and non-binary people are a key group in the HIV epidemic, who may 
be at higher risk of HIV acquisition due to a complex interplay between biological, 
social and structural factors. Furthermore, those living with HIV may experience 
poorer outcomes across the HIV care continuum.  However, we note the paucity of 
data on trans and non-binary people and HIV in the UK.  PHE’s lead on trans data 
inclusion, including ongoing work in utilising non-binary gender categories, needs to 
be followed by other health services.  We (RJ and ST) also look forward to 
publishing findings from our own qualitative study on the experiences of trans 
women living with HIV.  Furthermore, forthcoming British Association of Sexual 
Health and HIV (BASHH) guidelines on the sexual and reproductive healthcare of 
gender-diverse populations are an important step towards ensuring quality of care.  
Finally, it is important to acknowledge the important work of CliniQ, the UK’s leading 
holistic sexual health and well-being service for trans people (see 
https://cliniq.org.uk/).    
 
In 2016, leading trans activist Juno Roche convened a meeting bringing 
together a wide range of stakeholders including trans people, advocacy groups, 
clinicians and academics to set an agenda for research into trans people’s sexual 
health in the UK15.  The group identified a number of research priorities as well as 
highlighting the significant barriers to participation in research including concerns 
about stigma, fears about drug interactions, and previous experiences of 
discrimination within healthcare services.  It is therefore critical that future research is 
conducted in partnership with trans people in order to address these concerns.  It is 
time we acknowledge the significant gaps in our understanding of how HIV affects 
trans and non-binary people in the UK.  It is time we count trans and non-binary 
people.   
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